

地西他滨治疗老年急性髓系白血病的效果

丁 超

四川省遂宁市中心医院血液科 四川 遂宁 629000

【摘要】目的: 探究分析地西他滨治疗老年急性髓系白血病的临床效果及安全性。方法: 选取于 2019 年 1 月至 2022 年 8 月, 我院收治的老年急性髓系白血病患者共 100 例, 作为本次研究对象。根据患者的入院序列数为基础, 采用随机数字分组的方式, 将 100 例患者随机分为对照组以及观察组。对照组采用常规治疗模式进行干预; 观察组采用常规治疗模式结合地西他滨的治疗模式进行干预。对比分析对照组以及观察组的治疗有效率、血清学指标、生存质量以及并发症发生率。结果: 经治疗干预后, 观察组对比分析对照组以及观察组的治疗有效率、血清学指标、生存质量以及并发症发生率方面明显优于对照组, 其中 ($P < 0.05$), 差异具有统计学意义。结论: 在对老年急性髓系白血病患者进行治疗的过程中, 采用常规治疗模式结合地西他滨的治疗模式进行干预, 能够显著改善患者对比分析对照组以及观察组的治疗有效率、血清学指标、生存质量以及并发症发生率, 在实际应用的过程中具有优良的效果, 值得进一步的推广与应用。

【关键词】: 地西他滨; 老年急性髓系白血病; 治疗有效率; 并发症发生率

Effect of Decitabine on Elderly Patients with Acute Myeloid Leukemia

Chao Ding

Department of Hematology, Suining Central Hospital Sichuan Suining 629000

Abstract: Objective: To explore and analyze the clinical efficacy and safety of decitabine in the treatment of elderly acute myeloid leukemia. Methods: A total of 100 elderly patients with acute myeloid leukemia admitted to our hospital from January 2019 to August 2022 were selected as the research objects. Based on the number of admission sequence of patients, 100 patients were randomly divided into control group and observation group. The control group received conventional treatment. The observation group was treated with conventional treatment mode combined with decitabine. The effective rate, serological indexes, quality of life and incidence of complications were compared between the control group and the observation group. Results: After treatment intervention, the treatment efficiency, serological indexes, quality of life and incidence of complications of the observation group were significantly better than those of the control group, and the difference was statistically significant ($P < 0.05$). Conclusion: In the treatment of elderly patients with acute myeloid leukemia, USES the mode of conventional treatment of west he marina intervention treatment mode, can significantly improve the contrast analysis of the control group and observation group of patients with treatment efficient and serological indexes, the quality of life and complication rates, in the process of practical application is of good effect, It is worthy of further promotion and application.

Keywords: Decitabine; Elderly acute myeloid leukemia; Effective rate of treatment; Incidence of complications

前言

100

1 资料与方法

1.1

2019 1 2022 8
100

100

50

26 24

66-83

[1] 2019 1 71.04± 2.42

2022 8

50

25

25

66- 82	71.03± 2.40		P 0.05	2 结果			
				21			
						P 0.05	
					17		15
					18		64.00%
					31		17
1.2				2			96.00%
1.21				$\chi^2=16.000$ $P=0.001$			
				22			
	H10910093						
	15Mg	1				P 0.05	
1- 5							
H20055128							5
25mg	1- 15			5			2
	S19990028			4			32.00%
		1					0
300μ g		10× 10 ⁹ L		3			0
				3			12.00%
20× 10 ⁹ L	TPO	IL- 11		$\chi^2=5.828$ $P=0.016$			
				23			
1.2.2						P 0.05	
	H20143382						
	15mg/m ²	1			7		14.00%
					0		0.00%
				$\chi^2=7.527$ $P=0.006$			
				24			
1.3						P 0.05	
					VEGF		128.07± 11.98 ng L ⁻¹
	5%				VEGF		128.10± 12.02 ng L ⁻¹
		5%- 20%		$t=0.013$ $P=0.990$			
					VEGF		128.07± 11.98 ng L ⁻¹
	20%	=		$t=11.454$ $P=0.001$	VEGF		103.77± 9.03 ng L ⁻¹
					VEGF		128.10± 12.02 ng L ⁻¹
					VEGF		92.11± 8.00 ng L ⁻¹
1.4				$t=17.625$ $P=0.001$			
	SPSS23.0				VEGF		103.77± 9.03 ng L ⁻¹
	%	$P<0.05$			VEGF		92.11± 8.00 ng L ⁻¹

$t=6.834$ $P=0.001$
 bFGF 125.00 ± 12.17 ng L⁻¹
 bFGF 125.30 ± 12.20 ng L⁻¹
 $t=0.025$ $P=0.983$
 bFGF 125.00 ± 12.17 ng L⁻¹
 bFGF 97.44 ± 7.362 ng L⁻¹
 $t=13.054$ $P=0.001$
 bFGF 125.30 ± 12.20 ng L⁻¹
 bFGF 87.65 ± 7.44 ng L⁻¹
 $t=19.889$ $P=0.001$
 2.5

RNA
 DNA
 GI S
 DNA

DNA
 [4-5]

P 0.05

76.69 ± 6.75
 84.55 ± 7.12 $t=5.665$ $P=0.001$
 74.33 ± 5.75
 83.46 ± 6.27 $t=4.889$ $P=0.001$
 82.29 ± 7.42
 90.35 ± 7.54 $t=7.441$ $P=0.001$
 81.22 ± 7.00
 88.18 ± 7.49 $t=3.962$ $P=0.001$

3 讨论

69%

[2-3]

参考文献:

[1] . CHG [J]. ,2021,50 (05):795- 797.
 [2] . CAG Meta [J]. ,2020,29(08):488- 494.
 [3] . [J]. ,2020,39(03): 121- 123.
 [4] . CAG [J]. ,2019, 17(21):117- 118.
 [5] . CAG [J]. ,2018,30(19):25 - 27.